CTOs on the Move

Integrated Viral Protection

www.ivpair.com

 
World-Leading Biodefense Indoor Air Protection System™ Scientifically proven to destroy COVID-19 (99.999%) and Anthrax spores (99.98%) instantaneously in a single pass. Learn More Scientifically proven to Kill Sars-CoV-2, the virus that causes COVID-19...
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.ivpair.com
  • 7670, Woodway Drive
    Houston, TX USA 77063
  • Phone: 800.713.4872

Executives

Name Title Contact Details

Similar Companies

Natrol subsidiary of Plethico Pharmaceuticals Limited

Natrol, Inc. subsidiary of Plethico Pharmaceuticals Limited is a Chatsworth, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Xpress Wellness Urgent Care

Xpress Wellness provides urgent care, primary care, and occupational medicine. Walk in, check in online, or schedule a virtual visit today.

Johnson Matthey Pharmaceutical - West Deptford

Johnson Matthey Pharmaceutical - West Deptford is a Paulsboro, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Virtus Pharmaceuticals

Virtus Pharmaceuticals’ mission is to be the leading specialty niche pharmaceutical company providing the highest quality products through experienced leadership, innovative approaches and outstanding customer service.

Eupraxia Pharmaceuticals

Eupraxia is a clinical-stage biotechnology company focused on the development of locally delivered, extended-release alternatives to currently approved drugs. Each of Eupraxia`s product candidates has the potential to address therapeutic areas with high unmet medical need, and strives to provide improved patient benefit by delivering targeted, long-lasting activity with fewer side effects. In addition to Eupraxia`s lead product candidate, EP-104IAR, Eupraxia is developing a pipeline of earlier-stage long-acting formulations. Potential pipeline candidates include a range of drugs for indications such as post-surgical pain (EP-105), and post-surgical site infections (EP-201), each designed to improve on the activity and tolerability of approved drugs. Eupraxia is also developing a formulation of EP-104IAR for use in canine and equine osteoarthritis.